
€57,48 €47,50 excl. VAT
Glycogen storage disease II is a recessively inherited and often fatal disorder caused by the deficiency of acid α-glucosidase, an enzyme encoded by the GAA gene and needed to break down glycogen in lysosomes.
10 working days
From €5,95 shipping and administration per order (incl. VAT)
Specifications
Breeds | |
---|---|
Gene | |
Organ | |
specimen | Swab, Blood EDTA, Blood Heparin, Semen, Tissue |
Mode of Inheritance | |
Chromosome | |
Year Published |
General information
Glycogen storage disease II is a recessively inherited and often fatal disorder caused by the deficiency of acid α-glucosidase, an enzyme encoded by the GAA gene and needed to break down glycogen in lysosomes. The affected dogs mimic infantile-onset Pompe disease genetically, but also clinico-pathologically.
Clinical features
Deficiency of acid α-glucosidase leads to storage of glycogen inside lysosomes and eventually also to cytoplasmic glycogen storage. Ultimately, the accumulation of glycogen results in tissue destruction reflected by a spectrum of clinical phenotypes ranging from a fatal infantile form of Pompe disease to a slowly progressive late-onset form.
Additional information
Also called Pompe disease, Pompe's disease, acid maltase deficiency, and generalised glycogenesis type II.
References
Pubmed ID: 23457621
Omia ID: 419